Drug study to examine Alzheimer’s disease prevention, research Michigan participants
An as yet unapproved drug shows promise for reducing cognitive decline in patients with Alzheimer’s disease. Whether it might work to prevent disease progression is the question in a new clinical trial of lecanemab, a monoclonal antibody developed by Japanese pharmaceutical company Eisai and Biogen of Massachusetts. Michigan’s only site, at the University of Michigan …
Drug study to examine Alzheimer’s disease prevention, research Michigan participants Read More »